Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118553 | 0.91 | NPC1 (0.69) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4112443 | 0.88 | NPC1 (0.71) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4112362 | 0.88 | NPC1 (0.67) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4122903 | 0.87 | NPC1 (0.71) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4105335 | 0.86 | NPC1 (0.64) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4115616 | 0.86 | NPC1 (0.65) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4548132 | 0.85 | IDH1 (0.64) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4112064 | 0.85 | NPC1 (0.62) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4112024 | 0.84 | NPC1 (0.63) | NPC1RAB9AKMT2ALMNAMAPT | |
| SCHEMBL4118288 | 0.84 | NPC1 (0.59) | NPC1RAB9AKMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | NPC1 927/4885RAB9A 815/4885KMT2A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.